vs
Side-by-side financial comparison of ANAPTYSBIO, INC (ANAB) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
SMITH & WESSON BRANDS, INC. is the larger business by last-quarter revenue ($124.7M vs $108.2M, roughly 1.2× ANAPTYSBIO, INC). ANAPTYSBIO, INC runs the higher net margin — 45.8% vs 1.5%, a 44.3% gap on every dollar of revenue. On growth, ANAPTYSBIO, INC posted the faster year-over-year revenue change (151.1% vs -3.9%). ANAPTYSBIO, INC produced more free cash flow last quarter ($98.0M vs $16.3M). Over the past eight quarters, ANAPTYSBIO, INC's revenue compounded faster (288.3% CAGR vs -4.8%).
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for inflammatory diseases, immuno-oncology indications, and rare disease conditions. It primarily serves the U.S. market, advancing its innovative product candidate pipeline to address unmet medical needs via rigorous research and clinical development.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
ANAB vs SWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $108.2M | $124.7M |
| Net Profit | $49.6M | $1.9M |
| Gross Margin | — | 24.3% |
| Operating Margin | 61.8% | 3.3% |
| Net Margin | 45.8% | 1.5% |
| Revenue YoY | 151.1% | -3.9% |
| Net Profit YoY | 327.8% | -53.6% |
| EPS (diluted) | $1.64 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.2M | $124.7M | ||
| Q3 25 | $76.3M | $85.1M | ||
| Q2 25 | $22.3M | $140.8M | ||
| Q1 25 | $27.8M | $115.9M | ||
| Q4 24 | $43.1M | $129.7M | ||
| Q3 24 | $30.0M | $88.3M | ||
| Q2 24 | $11.0M | $159.1M | ||
| Q1 24 | $7.2M | $137.5M |
| Q4 25 | $49.6M | $1.9M | ||
| Q3 25 | $15.1M | $-3.4M | ||
| Q2 25 | $-38.6M | $8.6M | ||
| Q1 25 | $-39.3M | $2.1M | ||
| Q4 24 | $-21.8M | $4.5M | ||
| Q3 24 | $-32.9M | $-1.9M | ||
| Q2 24 | $-46.7M | $27.9M | ||
| Q1 24 | $-43.9M | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | 61.8% | 3.3% | ||
| Q3 25 | 45.5% | -3.5% | ||
| Q2 25 | -117.5% | 9.3% | ||
| Q1 25 | -99.2% | 4.1% | ||
| Q4 24 | -22.4% | 5.8% | ||
| Q3 24 | -75.8% | -1.7% | ||
| Q2 24 | -367.5% | 17.4% | ||
| Q1 24 | -587.8% | 8.2% |
| Q4 25 | 45.8% | 1.5% | ||
| Q3 25 | 19.8% | -4.0% | ||
| Q2 25 | -173.5% | 6.1% | ||
| Q1 25 | -141.6% | 1.8% | ||
| Q4 24 | -50.5% | 3.5% | ||
| Q3 24 | -109.4% | -2.1% | ||
| Q2 24 | -425.3% | 17.5% | ||
| Q1 24 | -612.0% | 5.7% |
| Q4 25 | $1.64 | $0.04 | ||
| Q3 25 | $0.52 | $-0.08 | ||
| Q2 25 | $-1.34 | $0.19 | ||
| Q1 25 | $-1.28 | $0.05 | ||
| Q4 24 | $-0.63 | $0.10 | ||
| Q3 24 | $-1.14 | $-0.04 | ||
| Q2 24 | $-1.71 | $0.60 | ||
| Q1 24 | $-1.64 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.2M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $37.2M | $363.2M |
| Total Assets | $364.4M | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.2M | $22.4M | ||
| Q3 25 | $109.8M | $18.0M | ||
| Q2 25 | $44.3M | $25.2M | ||
| Q1 25 | $98.6M | $26.7M | ||
| Q4 24 | $123.1M | $39.1M | ||
| Q3 24 | $191.6M | $35.5M | ||
| Q2 24 | $71.8M | $60.8M | ||
| Q1 24 | $53.7M | $47.4M |
| Q4 25 | $37.2M | $363.2M | ||
| Q3 25 | $-29.4M | $364.4M | ||
| Q2 25 | $-44.7M | $372.5M | ||
| Q1 25 | $34.0M | $366.9M | ||
| Q4 24 | $70.9M | $371.5M | ||
| Q3 24 | $84.4M | $380.0M | ||
| Q2 24 | $9.9M | $399.9M | ||
| Q1 24 | $47.8M | $376.4M |
| Q4 25 | $364.4M | $548.6M | ||
| Q3 25 | $353.1M | $554.6M | ||
| Q2 25 | $335.3M | $559.6M | ||
| Q1 25 | $422.1M | $578.9M | ||
| Q4 24 | $483.8M | $587.4M | ||
| Q3 24 | $493.4M | $571.3M | ||
| Q2 24 | $427.4M | $577.4M | ||
| Q1 24 | $405.8M | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $98.0M | $27.3M |
| Free Cash FlowOCF − Capex | $98.0M | $16.3M |
| FCF MarginFCF / Revenue | 90.5% | 13.1% |
| Capex IntensityCapex / Revenue | 0.0% | 8.8% |
| Cash ConversionOCF / Net Profit | 1.98× | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | $19.6M | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.0M | $27.3M | ||
| Q3 25 | $-27.4M | $-8.1M | ||
| Q2 25 | $-40.2M | $40.8M | ||
| Q1 25 | $-10.7M | $-9.8M | ||
| Q4 24 | $-66.7M | $-7.4M | ||
| Q3 24 | $-10.1M | $-30.8M | ||
| Q2 24 | $-21.3M | $43.7M | ||
| Q1 24 | $-37.3M | $25.2M |
| Q4 25 | $98.0M | $16.3M | ||
| Q3 25 | $-27.4M | $-12.4M | ||
| Q2 25 | $-40.3M | $33.5M | ||
| Q1 25 | $-10.7M | $-16.1M | ||
| Q4 24 | $-66.9M | $-10.7M | ||
| Q3 24 | $-10.1M | $-35.5M | ||
| Q2 24 | $-21.4M | $38.2M | ||
| Q1 24 | $-37.3M | $7.0M |
| Q4 25 | 90.5% | 13.1% | ||
| Q3 25 | -35.9% | -14.6% | ||
| Q2 25 | -180.9% | 23.8% | ||
| Q1 25 | -38.7% | -13.9% | ||
| Q4 24 | -155.3% | -8.3% | ||
| Q3 24 | -33.7% | -40.2% | ||
| Q2 24 | -194.6% | 24.0% | ||
| Q1 24 | -519.3% | 5.1% |
| Q4 25 | 0.0% | 8.8% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.2% | 5.2% | ||
| Q1 25 | 0.1% | 5.4% | ||
| Q4 24 | 0.6% | 2.5% | ||
| Q3 24 | 0.1% | 5.3% | ||
| Q2 24 | 0.3% | 3.5% | ||
| Q1 24 | 0.4% | 13.2% |
| Q4 25 | 1.98× | 14.22× | ||
| Q3 25 | -1.81× | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | — | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
